Crompton Greaves

Sharekhan has put a buy call on Crompton Greaves. The firm has set a price target of Rs 260 on the stock. "During post Q2 result conference call, the management sounded fairly positive on gradual recovery of its overseas operations and signs of improvement in order inflow," the company has said in its research report.

The Stock corrected as much as 8% on Thursday and Sharekhan sees this as a great buying opportunity.

V-Guard

Firstcall Research has placed a buy call on "V-Guard". The firm says that the company has a diversified client base and an extensive marketing & distribution network. Its client base differs from product to product and includes direct marketing agents, distributors and retailers. V- Guard has a strong network of 28 branches, over 230 distributors, 3,000 channel partners and 15,000 retailers across the country.

"We recommend ‘BUY' in this particular scrip with a target price of Rs 1005 for Medium to Long term investment," says Firstcall Research report.

Arvind Remedies

Ventura has said that Arvind Remedies has acquired patent rights of three drug products and tied up with a number of research institutes of repute for the same, and, a number of these drugs are in various stages of development. This pipeline seems promising and augurs well for the long run.

"The P/E of 4.0x implies a target price of Rs100 on its FY17 EPS of Rs 25/share. Any announcement of further capacity expansion and a higher than expected pick-up in growth and margins are upside triggers to our target price," says Ventura Research report.

GSFC

Emkay Global has set a price target of Rs 140 on GSFC. The firm feels that a reduction in net debt has led to significant improvement in balance sheet strength with net debt reducing by Rs 4.6 bn between FY14 and H1FY15.

"Going forward, with the commissioning of the nylon 6 expansion, water soluble fertilizer plant and completion of dredging at the Sikka unit we expect revenue growth momentum to continue in FY16E," the firm has said in its research report.

Syndicate Bank

Syndicate Bank has fallen from levels of Rs 180 to the current levels of Rs 114. The price to book value is a mere 0.60 times, while the dividend yield works close to 6 per cent. The price to earnings multiple is less than 4 times.